OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...
vegconomist9m
Ingredion Joins Forces with Oobli to Expand Access to Next-Gen Sweet Protein Solutions
Oobli, a biotechnology company specializing in sweet proteins, has announced a partnership with global ingredient solutions ...